Repaglinide Tablet
Product Images NDC 63629-4866

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Repaglinide (NDC 63629-4866). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl636294866)

Label (Lbl636294866)
The text provides information about a tablet containing Repaglinide USP 0.5 mg with NDC code 63629-4866-1. The usual dosage details are missing but direct to scan the package insert QR code for full prescribing information. Storage guidelines advise keeping the tablets at a temperature range of 20°C to 25°C (68°F to 77°F) and protecting from moisture by ensuring bottles are tightly closed. It is emphasized to keep the tablets out of reach of children. The package contains 30 tablets and should be dispensed in a tight container with child-resistant closure. The tablets are manufactured by Aurobindo Pharma Limited and repackaged by Bryant Ranch Prepack, Inc.*
FDA Label Image

Figure 1: Repaglinide In Combination With Pioglitazone: Hba1c Values (Repaglinide Fig1)

Figure 1: Repaglinide In Combination With Pioglitazone: Hba1c Values (Repaglinide Fig1)
This text seems to be a table showing the change in HbA1c (%) over time for different treatment options, including Repaglinide + Pioglitazone, Repaglinide, and Pioglitazone. The x-axis represents treatment weeks, while the y-axis represents the change in HbA1c (%). The data shows how the HbA1c values change over time for each treatment group.*
FDA Label Image

Chemical Structure (Repaglinide Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.